Publications

Beynon F, Langet H, Bohle L.F, Awasthi S, Ndiaye O, Machoki M'Imunya J, Masanja H, Horton S, Ba M, Cicconi S, Emmanuel-Fabula M, Faye P.M, Glass T.R, Keitel K, Kumar D, Kumar G, Levine G.A, Matata L, Mhalu G, Miheso A, Mjungu D, Njiri F, Reus E, Ruffo M, Schär F, Sharma K, Storey H.L, Masanja I, Wyss K, D'Acremont V, TIMCI Collaborator Group. The Tools for Integrated Management of Childhood Illness (TIMCI) study protocol: a multi-country mixed-method evaluation of pulse oximetry and clinical decision support algorithms. Glob Health Action. 2024;17:2326253. DOI: 10.1080/16549716.2024.2326253

Chatterjee R, Chan J, Mayles H, Cicconi S, Syndikus I. Long-term results of hypofractionated radiotherapy with intra-prostatic boosts in men with intermediate- and high-risk prostate cancer: a phase II trial. Clin Oncol (R Coll Radiol). 2024(in press). DOI: 10.1016/j.clon.2024.08.011

Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran C.M, Rawcliffe C, Sripadam R, Mukherjee S, Soonawalla Z, Wadsley J, Al-Mukhtar A, Dickson E, Graham J, Jiao L, Wasan H.S, Tait I.S, Prachalias A, Ross P, Valle J.W, O'Reilly D.A, Al-Sarireh B, Gwynne S, Ahmed I, Connolly K, Yim K.L, Cunningham D, Armstrong T, Archer C, Roberts K, Ma Y.T, Springfeld C, Tjaden C, Hackert T, Büchler M.W, Neoptolemos J.P, European Study Group for Pancreatic Cancer. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):157-168. DOI: 10.1016/S2468-1253(22)00348-X